Protagonist Therapeutics PTGX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.78M+132% | -$44.38M-134% | -$39.34M-18.5% | -$34.77M-13.6% | -$11.66M-106% | ||
| $407K+70.3% | $376K+219% | $361K+56.3% | $304K+26.1% | $239K+1.3% | ||
| $14.52M+5.2% | $10.7M+17.7% | $10.56M+3.9% | $10.91M+22.0% | $13.8M+47.6% | ||
| $3M+143% | $0— | $2.42M— | $375K— | $1.24M-56.2% | ||
| -$10.79M+8.7% | $5.41M+67.6% | —— | —— | -$11.82M-312% | ||
| $1.92M+102% | $365K— | $0-100% | $1.1M-45.4% | $948K+3.6% | ||
| -$2K-140% | —— | —— | $22.28M— | $5K— | ||
| -$3.27M+40.5% | -$7.44M— | -$3.08M— | -$5.01M— | -$5.5M-112% | ||
| —— | —— | —— | -$1.89M— | -$800K-124% | ||
| -$547K-260% | —— | -$581K-250% | —— | $341K— | ||
| -$48.94M-139% | —— | —— | —— | $125.36M+557% | ||
| $215K-60.6% | $144K-53.5% | $88K-88.6% | $813K+2,804% | $545K+125% | ||
| $68.97M-67.8% | $104.27M-8.9% | $161.12M-39.6% | $67.15M-61.6% | $214.04M+226% | ||
| $156.69M+38.4% | $153.23M+44.6% | $102.65M+74.8% | $122.78M+41.3% | $113.18M+57.2% | ||
| $90.89M+196% | —— | -$58.56M+71.9% | —— | -$94.4M-1,655% | ||
| $23.37M+96.1% | —— | $5.66M-53.0% | $2.93M+13.7% | $11.92M+52.9% | ||
| $23.37M+104% | $2.84M-29.6% | $5.66M-53.0% | $2.93M+13.7% | $11.44M+59.0% | ||
| $65.32M+54.0% | $14.68M+143% | —— | $28.96M-84.2% | $42.4M+399% | ||
| —— | $923.5K+141% | $923.5K+141% | $923.5K+141% | $923.5K+141% | ||
| $1.03M-55.2% | $1.34M-51.6% | $1.68M-40.7% | $1.91M+15.2% | $2.29M+41.7% | ||
| $3M+143% | $0— | $2.42M— | $375K— | $1.24M-56.2% | ||
| —— | —— | —— | —— | $22.83M— | ||
| -$547K-260% | —— | -$581K-250% | —— | $341K— | ||
| -$10.79M+8.7% | $5.41M+67.6% | —— | —— | -$11.82M-312% | ||
| $1.92M+102% | $365K— | $0-100% | $1.1M-45.4% | $948K+3.6% | ||
| $53.54M+132% | -$462K-100% | —— | —— | -$165M-157% | ||
| $439K-22.8% | $345K-17.5% | $106K-74.5% | $568K-12.7% | $569K-2.6% | ||
| $156.69M+38.4% | $153.23M+44.6% | $102.65M+74.8% | $122.78M+41.3% | $113.18M+57.2% | ||
| —— | —— | —— | —— | —— | ||
| $23.37M+96.1% | $2.84M-29.6% | $5.66M-53.0% | $2.93M+13.7% | $11.92M+52.9% | ||
| —— | —— | —— | —— | $479K-20.2% | ||
| $110K+233% | —— | —— | $70K-69.6% | $33K-26.7% | ||
| -$547K-260% | —— | -$581K-250% | —— | $341K— | ||
| —— | $923.5K+141% | $923.5K+141% | $923.5K+141% | $923.5K+141% | ||
| -$49.16M-139% | —— | —— | —— | $124.82M+551% | ||
| -$49.16M-139% | —— | —— | —— | $124.82M+551% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Protagonist Therapeutics generate?
- Protagonist Therapeutics (PTGX) generated $317.6M in operating cash flow over the trailing twelve months.
- What is Protagonist Therapeutics's free cash flow?
- After $1.3M of capital expenditures, Protagonist Therapeutics's free cash flow was $316.6M over the trailing twelve months, up 364.9% year over year.
- Where does Protagonist Therapeutics's cash flow data come from?
- Every line is extracted from Protagonist Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
